- Report
- October 2024
- 193 Pages
Global
From €3514EUR$3,545USD£2,917GBP
€3905EUR$3,939USD£3,241GBP
- Report
- December 2024
- 193 Pages
Global
From €4907EUR$4,950USD£4,073GBP
- Report
- August 2024
- 211 Pages
Global
From €3601EUR$3,633USD£2,989GBP
€5145EUR$5,190USD£4,270GBP
- Report
- August 2024
- 144 Pages
Global
From €2973EUR$2,999USD£2,468GBP
- Report
- July 2024
- 110 Pages
Global
From €4708EUR$4,750USD£3,908GBP
- Report
- July 2024
- 155 Pages
Global
From €3370EUR$3,400USD£2,798GBP
€4213EUR$4,250USD£3,497GBP
- Report
- March 2024
- 132 Pages
Global
From €4609EUR$4,650USD£3,826GBP
- Report
- April 2024
- 318 Pages
Global
From €5424EUR$5,663USD£4,350GBP
- Report
- April 2024
- 137 Pages
Global
From €2973EUR$2,999USD£2,468GBP
- Report
- November 2024
- 184 Pages
Global
From €3514EUR$3,545USD£2,917GBP
€3905EUR$3,939USD£3,241GBP
- Report
- November 2024
- 193 Pages
Global
From €3514EUR$3,545USD£2,917GBP
€3905EUR$3,939USD£3,241GBP
- Report
- October 2024
- 184 Pages
Global
From €3514EUR$3,545USD£2,917GBP
€3905EUR$3,939USD£3,241GBP
- Report
- October 2024
- 189 Pages
Global
From €3514EUR$3,545USD£2,917GBP
€3905EUR$3,939USD£3,241GBP
- Report
- October 2024
- 186 Pages
Global
From €3514EUR$3,545USD£2,917GBP
€3905EUR$3,939USD£3,241GBP
- Report
- October 2024
- 195 Pages
Global
From €3514EUR$3,545USD£2,917GBP
€3905EUR$3,939USD£3,241GBP
- Report
- October 2024
- 191 Pages
Global
From €3514EUR$3,545USD£2,917GBP
€3905EUR$3,939USD£3,241GBP
- Report
- October 2024
- 199 Pages
Global
From €3514EUR$3,545USD£2,917GBP
€3905EUR$3,939USD£3,241GBP
- Report
- October 2024
- 194 Pages
Global
From €3514EUR$3,545USD£2,917GBP
€3905EUR$3,939USD£3,241GBP
- Report
- October 2024
- 183 Pages
Global
From €3514EUR$3,545USD£2,917GBP
€3905EUR$3,939USD£3,241GBP
- Report
- October 2024
- 192 Pages
Global
From €3514EUR$3,545USD£2,917GBP
€3905EUR$3,939USD£3,241GBP
The Gastrointestinal Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat diseases and disorders of the gastrointestinal tract. These drugs are used to treat conditions such as irritable bowel syndrome, Crohn's disease, ulcerative colitis, and gastroesophageal reflux disease. Commonly prescribed drugs include antacids, proton pump inhibitors, and H2 receptor antagonists.
The Gastrointestinal Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck & Co., AstraZeneca, and Novartis. These companies are constantly developing new drugs and treatments to meet the needs of patients. Show Less Read more